Peace Moore
Women's Health · Larchmont, NYNPI 1598037319
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.4% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Astellas Pharma US Inc at 24.0% of the total. 2025 is the largest year on record at $852, 2.8 times the $307 reported in 2023.
Across 49 payments — averaging $30.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$359
- Sumitomo Pharma America, Inc.$313
- Shield Therapeutics Inc$240
- Exeltis, USA Inc.$211
- Mayne Pharma Commercial LLC$117
- Organon$109
- plus $144 from 4 others
What the payments were for
- Food & beverage$1,39493%
- Education$997%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 10 | $359 |
| Sumitomo Pharma America, Inc. | 13 | $313 |
| Shield Therapeutics Inc | 3 | $240 |
| Exeltis, USA Inc. | 4 | $211 |
| Mayne Pharma Commercial LLC | 7 | $117 |
| Organon | 5 | $109 |
| AbbVie | 3 | $61 |
| Agile Therapeutics, Inc. | 2 | $38 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Evofem Biosciences, Inc. | 1 | $21 |
How this compares
$1,493 in reported general payments places this provider in the 85th percentile of 376 women's health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Terconazole | 14 | $300 |
| Fluconazole | 16 | $70 |
Paid to pharmacies, not to this prescriber.
Other women's health in Larchmont
- Sophia FrontusBrooklyn$52K
- Austin JacobusNew York$51K
- Jenna HortonAlbany$37K
- Stacie WierWilliamsville$12K
- Jenna GoldsmithWilliamsville$9K
- Mollie FinkelAlbany$7K
- Marjorie Seale-SimpsonMiddletown$6K
- Stacy GarrityNew York$5K
- Sarah WeldNew York$5K
- Kathleen CsillagNew York$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.